Influenza A virus-IN-1, a dihydropyrrolidones derivative, is a highly effective inhibitor of various subtypes of influenza A virus (IAV) with IC 50 values ranging from 3.11 μM to 7.13 μM. It effectively suppresses IAV replication and enhances the expression of key antiviral cytokines, such as IFN-β, and the antiviral protein MxA.

A/FM-1/1/47 (H1N1):3.58 μM (IC50), A/PR/8/34 (H1N1) with NA-H274Y:6.48 μM (IC50), Influenza A virus 690 (H3):7.13 μM (IC50), A/Aichi/2/68 (H3N2):5.26 μM (IC50), A/Puerto Rico/8/34 (H1N1):3.11 μM (IC50)

Influenza A virus-IN-1 (compound 5-2; 5-40 μM; 24 hours; MDCK cells) treatment significantly decreases the yields of influenza viral NP in a dose-dependent manner. And the expression level of NP protein could also be restrained in a dose-dependent manner[1]. Influenza A virus-IN-1 (compound 5-2) treatment reduces influenza HA mRNA expression at all three time points[1]. Influenza A virus-IN-1 (compound 5-2) could efficiently inhibit replication of IAV and suppress the production of the NDAPH oxidase NOX1 in MDCK cells[1]. Western Blot Analysis[1]Cell Line: IAV-infected MDCK cells Concentration: 5 μM, 10 μM, 20 μM, 40 μM Incubation Time: 24 hours Result: Significantly decreased the yields of influenza viral NP in a dose-dependent manner.